Cover Image: May 2012 Scientific American Magazine See Inside

Return of the Clap

Gonorrhea, once a minor illness, is developing resistance to the last category of drugs that still works against it and could become untreatable















Share on Tumblr

Moving From East to West
Cephalosporin resistance has been emerging in Japan, and moving east and west from there, for at least a decade. In 1999 physicians in Kita­kyushu in southern Japan saw two men with gonorrheal infections that had not responded to the usual doses of cephalosporins or related drugs. Within two years more resistant cases emerged. A clinic in Hawaii treated a man with the standard dose of cefixime—a cephalosporin that comes in oral form—but he returned because his symptoms had not gone away. The man said he had had two sex partners who came from Japan, both women. One woman could not be found; the other woman and the man were cured only after receiving higher than usual doses of several different drugs.

Rapid international travel allowed the resistance mutation to hopscotch the globe. Sweden found its first case of the less susceptible strain in 2002. By 2005 it was in England. In 2010 Norway identified its first cases, in men who had had sex with women while traveling in the Philippines and Spain. That same year a Swedish man who contracted gonorrhea after having sex with a woman in Japan could not be cured until he received four times the standard dose of ceftri­axone, an injectable cephalosporin that doctors used because oral cefixime no longer worked. “We may now be reaching the ceftriaxone [doses] for which complete bacterial eradication ... will be impossible,” warned the physicians who treated him in a February 2011 report.

Last July Japanese researchers announced at a meeting in Canada that they had found a gonorrhea strain in a Kyoto sex worker that was “highly resistant” to both ceftriaxone “and most other antimicrobials tested.” The infection was finally controlled with intravenous antibiotics, but experts say that was a one-time fix, impractical for most clinics. In March other researchers announced a similar case in France.

“We can’t go back to older antibiotics,” says Peter Leone, who is board chair of the National Coalition of STD Directors and medical director of North Carolina’s STD prevention program. “Once resistance emerges in gonorrhea, it is there for good. Cephalosporins are all we have left.”

Uncertain What Comes Next
Efforts to control STDs may have inadvertently accelerated the spread of resistance. For years standard practice has been to quickly identify an infection, dole out the appropriate treatment and then move on to the next patient. If symptoms return, the assumption has been that the patient was reinfected. Experts now say that such patients may in fact have harbored resistant bacteria that were never killed in the first place—bacteria that the patients possibly spread to others.

Physicians would not have recognized that they were dealing with increasingly resistant bacteria, because the rapid tests most commonly used to diagnose sexual infections cannot identify resistant organisms. Instead the tests look for a DNA segment that is unique to gonorrhea, destroying the bacteria in the process. Identifying resistance requires intact living bacteria that researchers can grow in a lab dish and expose to antibiotics to see which drugs work or do not.

Routinely testing patients for resistant strains with the culture tests instead of rapid tests would be costly and time-consuming. But in the February New England Journal editorial, lead author Gail Bolan, director of the CDC’s division of STD prevention, argues that it is necessary. She also recommends retesting patients after treatment to make sure the infection is gone.

Doctors who treat sexually transmitted infections say that although such changes are sensible, they are not easy. Collecting bacterial samples for analysis requires supplies that most offices do not keep on hand, says Melanie Thompson, executive director of the AIDS Research Consortium of Atlanta, which also does STD testing. “A health care provider who suspected a resistant case would have to recognize it,” she explains, “contact the CDC or state health department to report it, go about getting the materials and then get the patient back in to give a sample.”



Rights & Permissions

5 Comments

Add Comment
View
  1. 1. Grumpyoleman 02:13 PM 5/11/12

    So the "gleep" is back. Thankfully, I'm too old to worry about it.

    Reply | Report Abuse | Link to this
  2. 2. stan e m 04:04 PM 5/14/12

    everyone should be tested(every six mnth) and marked if infected.Std would be extinct if this was done 50 yrs ago.

    Reply | Report Abuse | Link to this
  3. 3. jgrosay 09:46 AM 5/19/12

    In Spain, clap was called "Gota militar->Military drop", but some people having a connection with the army remark that gota militar can be also civilian and ecclesiastical.
    Those advocating screening test to detect hidden STDs must remember that the subject has been addressed before, and now there is an acceptably good image on in whom and how often screening tests are worth doing (See CDC). Even if you made, for example, HIV tests every other week in high risk people, you'll miss cases and never have a total interruption of the transmission chain, as an important window effect exists for detecting this and other transmissible diseases, and a person can be infected and pass the contagion to others in the few hours between one screening test and the next one. A change in habits would be the best approach to reduce the incidence of STDs, but taking into account how much we humans like sex, our innate preference for sexual drive over self-preservation instinct, and the previous generations' experiences about this, total erradication looks like an impossible task.

    Reply | Report Abuse | Link to this
  4. 4. carrotwax 01:32 AM 5/24/12

    As much as testing as desired, criminalization of sex with knowledge of an STD creates a disincentive for testing as is well known with HIV. Testing is a useful tool, but psychologically the ones who are most likely to contract STDs are also more likely to spread it via risky and compulsive behaviors.

    Furthermore, science is one thing but business models are another. Profit motive is what often determines research directions, not health or utilitarian goals. Vaccines can create massive benefit, but they are only bought once. I would like to see more vaccine research myself, but in an ever increasing profit driven system, there is likely going to be only limit research.

    Reply | Report Abuse | Link to this
  5. 5. missing link 07:07 AM 12/26/12

    Hi,

    I found this website to have a lot of information on Gonorrhea and other std's so I hope it helps some of you.
    http://www.the-clap.com

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

Tweets could not be retrieved at this time

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Return of the Clap: Scientific American Magazine

X
Scientific American MIND iPad

Tap into your MIND

Get Both Print & Tablet Editions for one low price!

Subscribe Now >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X